Matthew L. Posard
CIK 1543792 · Chief Commercial Officer · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HTI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HALO | Director | 53,709 | $128.01 | $6.88M | -$2.61M | 2 | 2026-10-02 |
| NAUT | Director | 130,000 | $2.44 | $317.2K | $225.5K | 6 | 2026-06-22 |
| HTI | Director | 77,835 | — | — | -$4.40M | 16 | 2026-05-07 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 4,167 | $2.84 | $11.8K | $1.00M | 3 | 2023-06-12 |
| DermTech, Inc. (DMTK) Delisted | Director | 158,215 | $0.09 | $14.9K | $1000.0K | 8 | 2023-06-05 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Chief Commercial Officer | — | — | — | $0 | 1 | 2016-01-06 |
| ILMN | Sr VP & General Manager | 30,858 | $271.04 | $8.36M | -$3.00M | 6 | 2013-05-30 |
Recent Filings · Page 2 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-13 | HTI | Sell (S) | −20,000 | -$1.01M | EDGAR |
| 2024-06-11 | HALO | Notice (144) | −20,000 | -$1.00M | EDGAR |
| 2024-04-29 | HTI | Grant (A) | +6,501 | $0 | EDGAR |
| 2023-06-16 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | Talis Biomedical Corp (TLIS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +35,714 | $0 | EDGAR |
| 2023-05-09 | HTI | Grant (A) | +8,065 | $0 | EDGAR |
| 2022-12-06 | HTI | Sell (S) | −30,000 | -$1.71M | EDGAR |
| 2022-06-16 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | Talis Biomedical Corp (TLIS) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.